EPO Upholds Stay on Mirrx Patent Proceedings as Santaris Pushes Ahead with HCV Rx

Earlier this year, Santaris sued Mirrx for allegedly using illegally obtained trade secrets to file European patent applications on a miRNA-inhibiting technology with therapeutic applications. The legal battle has raised questions about Santaris' HCV drug miravirsen.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.